Critical appraisal of ramelteon in the treatment of insomnia

Ramelteon is the first member of a novel class of hypnotics and acts as a selective melatonin receptor agonist. In 2005, ramelteon was approved by the US Food and Drug Administration for the treatment of insomnia characterized by sleep onset problems. Its unique mechanism of action made it a promisi...

Full description

Bibliographic Details
Main Authors:	Mets, Monique AJ, van Deventer, Kenny R, Olivier, Berend, Verster, Joris C
Format:	Online
Language:	English
Published:	Dove Medical Press 2010
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630951/

id	pubmed-3630951
recordtype	oai_dc
spelling	pubmed-36309512013-04-24 Critical appraisal of ramelteon in the treatment of insomnia Mets, Monique AJ van Deventer, Kenny R Olivier, Berend Verster, Joris C Review Ramelteon is the first member of a novel class of hypnotics and acts as a selective melatonin receptor agonist. In 2005, ramelteon was approved by the US Food and Drug Administration for the treatment of insomnia characterized by sleep onset problems. Its unique mechanism of action made it a promising candidate compared with the widely used hypnotics that act on the benzodiazepine receptor complex. Several studies have examined its efficacy and safety as a hypnotic agent. The primary efficacy of ramelteon was found to lie in a decrease in latency to persistent sleep, as measured by polysomnographic tests. Other sleep-related measures, such as total sleep time and number of nightly awakenings, show less pronounced improvement when treated with ramelteon. In addition, no rebound insomnia or abuse potential was observed in clinical studies. Although additional studies are necessary, current data on the acute and next-morning effects of ramelteon did not indicate cognitive or psychomotor impairment. Overall, ramelteon is safe and well tolerated, although some questions remain regarding its long-term efficacy and safety. These issues and possibilities for use in other patient groups should be addressed in future research. Dove Medical Press 2010-11-10 /pmc/articles/PMC3630951/ /pubmed/23616713 http://dx.doi.org/10.2147/NSS.S6846 Text en © 2010 Mets et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Mets, Monique AJ van Deventer, Kenny R Olivier, Berend Verster, Joris C
spellingShingle	Mets, Monique AJ van Deventer, Kenny R Olivier, Berend Verster, Joris C Critical appraisal of ramelteon in the treatment of insomnia
author_facet	Mets, Monique AJ van Deventer, Kenny R Olivier, Berend Verster, Joris C
author_sort	Mets, Monique AJ
title	Critical appraisal of ramelteon in the treatment of insomnia
title_short	Critical appraisal of ramelteon in the treatment of insomnia
title_full	Critical appraisal of ramelteon in the treatment of insomnia
title_fullStr	Critical appraisal of ramelteon in the treatment of insomnia
title_full_unstemmed	Critical appraisal of ramelteon in the treatment of insomnia
title_sort	critical appraisal of ramelteon in the treatment of insomnia
description	Ramelteon is the first member of a novel class of hypnotics and acts as a selective melatonin receptor agonist. In 2005, ramelteon was approved by the US Food and Drug Administration for the treatment of insomnia characterized by sleep onset problems. Its unique mechanism of action made it a promising candidate compared with the widely used hypnotics that act on the benzodiazepine receptor complex. Several studies have examined its efficacy and safety as a hypnotic agent. The primary efficacy of ramelteon was found to lie in a decrease in latency to persistent sleep, as measured by polysomnographic tests. Other sleep-related measures, such as total sleep time and number of nightly awakenings, show less pronounced improvement when treated with ramelteon. In addition, no rebound insomnia or abuse potential was observed in clinical studies. Although additional studies are necessary, current data on the acute and next-morning effects of ramelteon did not indicate cognitive or psychomotor impairment. Overall, ramelteon is safe and well tolerated, although some questions remain regarding its long-term efficacy and safety. These issues and possibilities for use in other patient groups should be addressed in future research.
publisher	Dove Medical Press
publishDate	2010
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630951/
_version_	1611971371098701824

Critical appraisal of ramelteon in the treatment of insomnia

Similar Items